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We have generated mice having a single copy of the
human haptoglobin gene (Hp2), driven by its natural
promoter, and a neomycin resistance gene (Neo), driven
by a herpes simplex thymidine kinase promoter with
polyoma enhancers, inserted into two defined chromo-
somal locations, the Hprt locus on the X-chromosome
and the apolipoprotein (apo) AI-CIII gene cluster on
chromosome 9. The haptoglobin promoter is highly spe-
cialized in its tissue of action; the viral promoter has few
restrictions. The apoAI-CIII gene is naturally active in
only two tissues, whereas the Hprt gene region is ubiq-
uitously active. Expression of both transgenes at sub-
stantial levels was achieved only (a) when the trans-
genes were inserted into the genome close to a known
tissue-specific enhancer/locus control region in the
apoAI-CIII gene cluster, and (b) when known conditions
for function of their promoters were met. The specifici-
ties of the two chromosomal regions and of the two
promoters are preserved, but their interactions are not
specific. We conclude that transgenes are affected by
locus-related enhancers in the same manner as nearby
endogenous genes. Our experiments reinforce the use-
fulness of using gene targeting to direct single-copy
transgenes to appropriate chromosomal locations.
Transgenic mouse technology has been widely and effectively
used for studying the physiological consequences of expressing
exogenous gene products or analyzing promoter function and
protein structure-function relationships in vivo (1). However,
analysis with transgenic mice produced by pronuclear micro-
injection requires multiple founders because a foreign gene
incorporated into the mouse genome is often expressed differ-
ently, both in amount and in tissue specificity in one founder
versus in another. Integration of the exogenous DNA into ran-
dom chromosomal locations and in unpredictable numbers of
copies, together with rearrangements in the introduced DNA or
in the sites of incorporation associated with the integration
event, are among the factors accounting for these variations (2,
3).
We have previously described a general way of introducing
single-copy transgenes into the mouse germ line via embryonic
stem (ES)1 cell technology as a means of comparing the expres-
sion of different transgenic sequences without the complica-
tions of variation in copy number and insertion site (4). In this
earlier work, we tested the method by inserting into the hypox-
anthine phophoribosyltransferase (Hprt) locus on the X chro-
mosome a single copy of a murine Bcl-2 cDNA driven either by
a chicken b-actin promoter or by a human b actin promoter and
demonstrated that expression of the two transgenes differed in
a predictable fashion. The Hprt gene is a housekeeping gene,
transcriptionally active in all tissues, and modification of the
locus does not affect the overall development and health of the
animals. Furthermore, the availability of Hprt2 ES cells, such
as E14TG2a (5) and HM-1 (6) and of vectors capable of medi-
ating highly efficient and directly selectable homologous recom-
bination at the Hprt locus makes this system simple to use. The
previous work, however, also showed that despite expression of
the Hprt locus in all tissues, expression of the Bcl-2 transgene
driven by the human or the chicken b actin promoter was very
low or undetectable in the liver and kidney; this has prompted
us to search for a locus in which liver-specific expression of a
targeted transgene can be readily studied.
A gene cluster on mouse chromosome 9, which contains
genes, coding for apolipoprotein (apo) A-I, apoC-III, and
apoA-IV is a potential target for such studies. The region is
relatively easily targeted (7), and alteration of a single copy of
any of the three genes in the locus has physiologically insignif-
icant consequences that do not affect the development or over-
all health of the resulting mice (8). All three apolipoprotein
genes are expressed highly in the liver and small intestine, and
the promoter/enhancer elements controlling the expression of
these genes are well characterized in humans.
In the present study, we tested the expectation that the
choice of the site of transgene insertion will cause a predictable
influence on the tissue-specific expression of an inserted trans-
gene. To do this, we introduced a transgene cassette into two
different chromosomal locations in mice: the apoAI-CIII locus
on chromosome 9 and the Hprt locus on the X chromosome. The
targeting cassette was composed of a neomycin resistance (Neo)
gene driven by the herpes simplex thymidine kinase promoter
with polyoma enhancers (9) and a human haptoglobin (Hp)
gene driven by its own 1.1-kb promoter sequence (10); hapto-
globin is the major hemoglobin-binding protein in serum, and
its gene is mainly expressed in the liver. Our results demon-
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of the two promoters are preserved, but their interactions are
not specific.
EXPERIMENTAL PROCEDURES
The Neo-hHp2 Transgene Cassette—The entire human Hp2 gene (10)
is contained within a 9-kb fragment extending from an XbaI site at
approximately 1.1 kb 59 to the starting codon to an ApaI site 1.6 kb 39
to the stop codon. This fragment with 1.1-kb DNA encoding the
pMC1neopoly(A) gene (Stratagene) attached to its 59 end in the opposite
transcriptional orientation was used as a Neo-hHp2 transgene cassette.
Gene Targeting—The vector to introduce the Neo-hHp2 cassette into
the Hprt locus was a modified form of the previously described locus-
specific targeting vector, pMP8 (14). The regions of homology are 4 kb of
DNA 59 to the Hprt locus and 1.6 kb of DNA extending 39 from a HindIII
site in intron 2 to an EcoRI site in intron 3 of the Hprt gene. The Neo
gene and the hHp2 gene were inserted as shown in Fig. 1.
A 9-kb BamHI fragment of mouse genomic DNA containing the
Apoa-1 gene and a 39 part of the Apoc-3 gene (7) was used to make the
targeting construct designed to insert the Neo-hHp2 cassette into the
apoAI-CIII region. The Neo-hHp2 cassette was inserted so as to replace
a 450-bp BglII-BstXI fragment 39 to the Apoc-3 gene. The BstXI site is
at 30 bp downstream of the poly(A) addition signals for the Apoc-3
transcripts. A herpes simplex thymidine kinase gene was placed at the
39 end of the construct (Fig. 2).
Cell culture, electroporation and selection using mouse ES cells
(BK4, a subclone of E14TG2a, provided by Dr. B. Koller, University of
North Carolina) were as described (7) Microinjection of ES cells and
derivation of transgenic mice were as described (15). Mice were main-
tained according to NIH/Institutional guidelines.
Southern Blot Analyses—Southern blots were made with HindIII
digests of genomic DNA isolated from cells or from tails of mice at
weaning (3 mg). Probe 1 (Fig. 1C) is a 250-bp RsaI fragment in the
intron 3 of the mouse Hprt gene. Probe 2 (Fig. 2C) is a 600-bp KpnI-
BamHI fragment containing a part of the Apoc-3 gene. The presence of
a 7.6-kb with probe 1 or an 8-kb band with probe 2 detects targeting in
the Hprt locus or apoAI-CIII region.
LPS Treatment—Inflammation was induced in mice (10–18 months
old) by injecting 25 mg of lipopolysaccharide (LPS, Calbiochem) intra-
peritoneally. Blood was collected retroorbitally 24 h after LPS injection.
Tissues were collected at 12 h after LPS injection for RNA analyses by
primer extension and at 24 h for Northern blot analyses.
Detection of Plasma Haptoglobin Protein—Sera (4–5 ml) were mixed
with 1 ml of a fresh lysate of red blood cells containing approximately 3%
hemoglobin and electrophoresed in a 5% polyacrylamide gel at pH 8.9
(16). The gels were soaked in 0.1 M potassium acetate, pH 5.0, for 15 min
before staining with 0.2% benzidine (w/v) in 0.5% acetic acid (v/v)
containing 0.3% hydrogen peroxide (w/v).
Northern Blot Analyses—Total RNA was isolated using TRI
REAGENT (Molecular Research Center, Inc.) according to the manu-
facturer’s protocol. RNA was electrophoresed in a 1.2% agarose gel
containing 2.2 M formaldehyde before transfer onto a Nytran Plus
membrane (Schleicher & Schuell). The blots were sequentially hybrid-
ized to probes using conventional protocols. The human haptoglobin b
probe was a 650-bp BamHI-HindIII fragment corresponding to exon 7 of
the Hp2 gene. The mouse apoA-I probe was a 180-bp EcoRI-NheI frag-
ment corresponding to exon 4. The mouse apoC-III probe was a 410-bp
SauIIIA fragment corresponding to exon 4. The mouse apoA-IV probe
was a 321-bp PvuII fragment corresponding to exon 3. The Neo probe
was a 380-bp PstI-NcoI fragment in pMC1neopoly(A). The Gapdh probe
was a 315-bp SacI-BamHI fragment corresponding to exons 5 through
8 (pTRI-GAPDH-mouse, Ambion).
Primer Extension Analyses—Oligonucleotide primers were labeled
with [g-32P]ATP (1.3 3 107 cpm/pmol) and incubated for 10 min at 68 °C
with 20 mg of total RNA in 30 ml of 0.05 M PIPES buffer, pH 6.4,
containing 0.2 M NaCl. The reaction mixture was then incubated over-
night at 42 °C before treatment with reverse transcriptase, as described
(17). The reaction products were resolved in a 20% polyacrylamide gel
containing 8.3 M urea. Gels were then dried and exposed to Kodak XAR
films for at least two different times. Densitometoric analyses were
performed using NIH Image, and the relative amount of mouse Hp,
human Hp2, or Neo transcripts were estimated in each sample by the
intensities of corresponding bands relative to that of Gapdh. The
following primers were used: 59-GCCACAGGCAGCATGACATACTT-39
for haptoglobins (nucleotides 901–923 of human Hp2 (10), 761–783 of
mouse, (18)); 59-ACCCATCACAAACATGGGGGCAT-39 for mouse
Gapdh (nucleotides 420–442(19)); and 59-CCGATCCCCTCAGAAGAA-
CTCTCGA-39for Neo (nucleotides 1522–1544). The validity of the assay
for quantitating amounts of transcript was established by the linearity
of the signal for the Hp and the Gapdh genes over a range of total liver
RNA from 0 to 40 mg and with primer amount varying from 0 to 105
cpm. Because the haptoglobin primer hybridizes to both human and
mouse transcripts equally well, the relative amounts of transcripts
within a sample can be readily compared. For comparisons between
samples or between different experiments, the expression levels were
adjusted against that of Gapdh with the caution that the normalized
values in different tissues may not be completely comparable, because
expression of Gapdh itself is somewhat variable in different tissues
(20).
Reverse Transcription-Polymerase Chain Reaction Analyses (RT-
PCR)—Total RNA (1 mg) was treated with DNase I and used in a
reverse transcription-polymerase chain reaction (RT-PCR) using a
standard protocol (21). The primers specific to human Hp2 were 59-A-
GAAGGAGATGGAGTATACACC-39 and 59-TTAAGGTGTACACTCCA-
TCTCC-39 (10) and specific to mouse Hp were 59-CAGTGCCCGAGAA-
GAAAAACTT-39 and 59-TACACAGAGCGACTTGAACA-39 (18). After
initial incubation at 95 °C for 2 min, PCR for 35 cycles was at 60 °C for
1 min, 72 °C for 1 min, 94 °C for 30 s, followed finally by 72 °C for 4 min.
Nuclear Run-on—Isolation of liver nuclei and in vitro nuclear run-on
assay were carried out according to Ntambi (22). The resulting radio-
active RNA was hybridized to immobilized DNA probes for apoC-III,
apoA-I, Neo, and Gapdh described above.
RESULTS
Generating Mice with Transgenes in the Hprt and ApoAI-CIII
Locus—The two genes chosen as transgenes for the present
study are the human haptoglobin transgene (hHp2) on a 9-kb
fragment of human genomic DNA that includes the hHp2 gene
with its own promoter and 39 untranslated sequence and neo-
mycin-resistant gene (Neo) from the pMC1neopoly(A). The two
genes are in opposite transcriptional orientations.
The overall scheme for inserting the Neo-hHp2 transgene
cassette into the partially deleted Hprt locus on the X chromo-
some of BK4 ES cells is diagrammed in Fig. 1. The targeting
vector is derived from pMP8SKB (14) used in our previous
studies of targeted transgenesis at this locus. In the current
vector, the promoter and exons 1 and 2 of the Hprt genes in
pMP8SKB were removed, and selection to facilitate identifica-
tion of targeted cells was with G418 instead of with hypoxan-
thine-aminopterin-thymidine. Approximately 1 in 10 G418-re-
sistant colonies had a single copy of the transgene inserted into
the Hprt locus. Because the ES cell used for targeting is karyo-
typically male, and thus hemizygous for the X-chromosome-
linked Hprt locus, the modified ES cell genome was transmit-
ted from the chimeras to their F1 female offspring. Mating of
these F1 heterozygous females with C57BL/6 males was used
to generate male progeny, and Southern blot analyses of their
genomic DNA showed either a 7.1-kb or a 7.6-kb HindIII frag-
ment, corresponding to the wild type or targeted Hprt locus
(Fig. 1D). We designate the resulting hemizygous males having
one copy of the hHp2 transgene on their X chromosomes as
Hprt-Hp2 mice.
The scheme for inserting the Neo-hHp2 transgene cassette
into the apoAI-CIII gene cluster on chromosome 9 is dia-
grammed in Fig. 2. The transgene replaces a 450-bp BglII/
BstXI fragment between the Apoa-1 and Apoc-3 genes. Approx-
imately one in three colonies resistant to G418 and ganciclovir
had an insertion of the transgene at the correct position as
judged by the presence in Southern blot analyses of an 8-kb
HindIII fragment in addition to a 12-kb band from the unmod-
ified locus. The transgene was passed from chimeric males to
approximately half of their offspring. We designate the result-
ing (heterozygous) mice carrying one copy of the hHp2 trans-
gene as Apo-Hp2 mice. Males at the F2 or F3 generation were
used for further experiments.
Expression of a Neomycin Resistance Transgene in the Apo-
Hp2 and Hprt-Hp2 Mice—Because the Neo gene in the Neo-
hHp2 transgene cassette is driven by a powerful herpes simplex
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thymidine kinase promoter and a duplicated polyoma en-
hancer, the Neo transgene was expected to be expressed in
most cell types regardless of the location of insertion (9). We,
therefore, first determined the tissue distribution and relative
levels of Neo transgene expression in the Apo-Hp2 and Hprt-
Hp2 mice. The Neo transcripts were detectable by Northern
blotting in the liver and small intestine of the Apo-Hp2 mice
but not in the Hprt-Hp2 mice (Fig. 3). Comparison of the levels
of Neo transcripts in different tissues was carried out by primer
extension analyses as illustrated in Fig. 4A for the liver and 4B
for the small intestine. Fig. 4C summarizes these and also
presents analyses of RNA from lung, adipose tissue, bone mar-
row, and spleen. The results show that expression of the Neo
transgene in the apoAI-CIII gene cluster differs considerably in
different tissues. However, in general, the relative levels of
expression in the various tissues parallel to that of the Apoa-1
and Apoc-3 genes, which are highly expressed in the liver and
small intestine. Thus, relative to liver expression as 100%, the
amounts of Neo transcripts per mg of total RNA in small intes-
tine, adipose tissue, and lung were 57, 14, and 3% that of the
liver. No Neo transcripts were detectable in the spleen and
bone marrow.
Expression of the Neo transgene in the Hprt-Hp2 mice was
detectable but low, at about 0.5% the expression of the Gapdh
gene in the same tissues, except that no expression was detect-
able in the small intestine; the expression in the liver of the
Neo gene in the Hprt locus was about 10% that in the apoAI-
CIII locus.
Expression of the Human Hp2 Transgene in the Apo-Hp2
Mice—Liver is the major organ of haptoglobin production in
humans and in mice. Northern blot analysis of liver total RNA
(Fig. 3A) using a probe (hpb) derived from the b region of the
human Hp2 gene showed that human haptoglobin transcripts
were readily detectable in the Apo-Hp2 mice. The level of
expression in the transgene homozygotes with two copies of the
transgene was approximately twice as much as that in the
single copy heterozygotes. Human Hp2 transcripts were also
detectable by Northern blot in the intestine of the Apo-Hp2
mice, but in considerably less amounts (Fig. 3B). Expression of
the endogenous mouse Hp gene (detectable by a low level
cross-reaction of its mRNA with the hpb probe) was stimulated
FIG. 1. Insertion of the Neo-hHp2 transgenes into the mouse
Hprt gene locus on the X chromosome. A, the partially deleted Hprt
gene (DHprt) of BK4 ES cells. The numbered black rectangles denote
exons. The double arrow indicates the 7.1-kb HindIII fragment charac-
teristic of the endogenous partially deleted Hprt gene. The open arrow
indicates the direction of the gene, and the vertical zig-zag line repre-
sents the deletion. B, H, R, and S indicate BamHI, HindIII, EcoRI, and
SalI sites, respectively. B, the targeting construct. Neo indicates the
neomycin resistance gene oriented as indicated by the arrow. The wavy
lines indicate plasmid sequences (not drawn to scale). The two shaded
areas represent the homologous regions in which recombination occurs.
C, the inserted Neo-hHp2 in the Hprt gene locus. Probe 1 is used to
demonstrate the 7.6-kb HindIII fragment characteristic of the inserted
hHp2 gene. D, autoradiogram with probe 1 of a Southern blot of F2
mouse genomic DNA digested with HindIII, showing the expected frag-
ments for the wild type (7.1 kb) and targeted alleles (7.6 kb). X/Y and
X/X are DNA from wild type animals; T/Y and T/X are from animals
carrying the targeted X chromosome.
FIG. 2. Insertion of the Neo-hHp2 transgenes into the mouse
apoAI-CIII gene locus on chromosome 9. A, the endogenous apoAI-
CIII locus. B, the targeting construct. C, the inserted Neo-hHp2 trans-
genes in the apoAI-CIII gene locus. The symbols are as in Fig. 1, with
additional restriction sites for BglII, BstI, and NheI labeled Bgl, Bst,
and Nh. TK indicates the herpes thymidine kinase gene. The double
headed arrow indicates the 8-kb HindIII fragment characteristic of the
inserted hHp2 gene. D, Southern blot analysis of tail DNA. DNA sam-
ples were isolated from the tails of 3-week-old animals resulting from
heterozygote matings. Probe 2 was used to identify the 8.0-kb HindIII
band diagnostic of the modified Apoc-3 gene. Animal 1 is wild type
(1/1); animals 2, 3, and 5 are heterozygous (T/1) for the insertion;
animals 4 and 5 are homozygous (T/T) for the insertion.
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by LPS in the liver but not in the intestine.
To compare the expression of the human Hp2 transgene with
the expression of the endogenous mouse haptoglobin gene in
tissues where the levels are too low for Northern blot analysis,
we used primer extension analyses as illustrated in Figs. 5A
through 5D and presented in a quantitative manner in Fig. 5E.
The data show that the endogenous mouse Hp gene is ex-
pressed at about 15% that of the liver level in lung, adipose
tissue, and bone marrow, respectively. Endogenous mouse Hp
transcripts were also detected (not shown) in the thymus and
FIG. 3. Northern blot analysis of the
mRNA from liver (A) and small intes-
tine (B). RNAs blots were sequentially
hybridized to the six probes indicated.
The haptoglobin probe was used first; it is
a fragment corresponding to the b sub-
unit of hHp2. Subsequent probes were
specific for the genes coding for Apoa-1,
Apoc-3, Apoa-4, Neo, and Gapdh. RNAs
were collected without treatment (LPS 2)
on 24 h after LPS injection (LPS 1). Each
lane contained 15 mg of total RNA. WT,
wild type.
FIG. 4. Primer extension analysis of
expression of the Neo transgene.
mRNAs (20 mg) from the liver (A) and
from the small intestine (B) of the indi-
cated animals were subjected to primer
extension analyses with Neo primer (105
cpm) and with GAPDH primer (105 cpm).
LPS1 or LPS2 indicate RNA from 12 h
after LPS injection or from untreated
mice. C, densitometric analyses of the Neo
gene expression in various tissues from
the Apo-Hp2 and the Hprt-Hp2 mice. The
values are means of three mice S.E. and
are expressed relative to the signals of
Gapdh in the liver as 100. LI, LU, AD,
BM, SP, and SI are liver, lung, adipose
tissue, bone marrow, spleen, and small
intestine. WT, wild type.
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adrenal gland at approximately 5% that of the liver, with still
lesser amounts in the intestine, spleen, kidney, and testis.
Increased expression of the mouse gene was observed in the
liver after LPS treatment, which is known to induce synthesis
of haptoglobin, an acute-phase response protein. The amount of
human Hp2 transcripts in the liver of Apo-Hp2 mice from a
single copy of the transgene was approximately 70% that of a
single copy of the endogenous mouse Hp gene. The mRNA
levels of both the endogenous mouse Hp gene and the hHp
transgene were increased equally by about 30% at 12 h after
LPS treatment. Human Hp2 transcripts were also found in the
small intestine, lung, adipose tissue, bone marrows, and
spleen, at about 3% of the liver expression of the endogenous
mouse gene. Less than 1% of liver levels of transcript were seen
in the other tissues examined (not shown), including brain,
thymus, heart, kidney, adrenal gland, testis, and ovary. In
general, expression of the human transgene in the Apo-Hp2
mice in these extra-hepatic tissues was approximately half or
less of the endogenous mouse gene expression, except that in
the intestine expression of the transgene, which was approxi-
FIG. 5. Primer extension analysis of
expression of the hHp2 transgene.
mRNAs (20 mg) from the liver (A), lung
(B), small intestine (C), and spleen (D)
were analyzed as in Fig. 4 with primers
for haptoglobin (105 for the liver and 106
cpm for other tissues) and GAPDH (105
cpm). E, densitometric analyses of the en-
dogenous mouse Hp gene in wild type
(WT) mice (hatched bars) and the hHp2
transgene (shaded bars) in Apo-Hp2 and
Hprt-Hp2 mice. The values are means of
three mice with S.E. and are expressed as
haptoglobin signal/gene copy/mg of RNA
relative to the signal for Gapdh in the
liver as 100. LI, LU, AD, BM, SP, and SI
are liver, lung, adipose tissue, bone mar-
row, spleen, and small intestine.
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mately five times that of the mouse gene (itself very low at
approximately 1.5% of the liver expression).
Expression of the hHp2 Transgene in the Hprt-Hp2 Mice—In
the Hprt-Hp2 mice, the level and tissue distribution of trans-
gene expression was markedly different from that in the Apo-
Hp2 mice. No transcripts of the hHp2 transgene were detecta-
ble by primer extension analyses in the liver, adipose tissue,
small intestine, and kidney in the Hprt-Hp2 mice, although
they were detectable when total RNA was subjected to RT-PCR
analyses (data not shown). Transcripts, detectable by primer
extension analyses in the lung, bone marrow, and spleen, were,
respectively, at about 4, 3, and 2% levels of the endogenous
mouse gene in the liver. Expression in the brain, heart, and
testis was detectable but at less than 1% of the liver expression
(data not shown). LPS treatment did not affect expression of
the transgene in any of these tissues.
Influence of the Neo-hHp2 Transgenes on the Expression of
Nearby Apolipoprotein Genes—To investigate whether the in-
sertion of the transgene 39 to the Apoc-3 gene had influenced
the expression of the nearby Apoa-1, Apoc-3, and Apoa-4 genes
in the Apo-Hp2 mice, the Northern blots used for Fig. 3 were
sequentially rehybridized with probes corresponding to each of
these apolipoprotein genes. The amounts of Apoa-1 and Apoa-4
transcripts in the Apo-Hp2 mice were not different from those
in the wild type mice. However, the amount of Apoc-3 tran-
scripts was reduced to about 50% that of wild type in heterozy-
gotes, and transcripts were not detectable in homozygous Apo-
Hp2 mice. Thus the insertion of the transgene cassette
approximately 30 bp 39 to the poly(A) addition signal sequence
affected the Apoc-3 gene expression, although the transcrip-
tional orientations of the Neo genes and the Apoc-3 genes are
opposed (Fig. 2). A preliminary nuclear run-on experiment with
the liver of a homozygous Apo-Hp2 mouse showed that initia-
tion of the Apoc-3 gene transcription appears to be normal
(data not shown). This suggests that the likely cause of the
undetectable amounts of Apoc-3 gene mRNA in the Apo-Hp2
homozygotes is that insertion of the transgenes just down-
stream of the gene results in an unstable message or in failure
of the transcripts to be processed properly. The levels of expres-
sion of the Apoa-1, Apoc-3, Apoa-4, and the Neo genes were
unaltered by LPS treatment.
Ready Detection of Human Haptoglobin in the Plasma of the
Apo-Hp2 Mice but Not in the Hprt-Hp2 Mice—We compared the
levels of the endogenous and human haptoglobin proteins in
the circulation of the transgenic mice by nondenaturing poly-
acrylamide gel electrophoresis of plasma proteins at pH 8.9
(Fig. 6). The amount of endogenous mouse haptoglobin differs
in the plasma of different individuals, with no protein being
detected in some mice. Plasma haptoglobin levels are much
more variable than the corresponding mRNA levels of the an-
imals. Reliable detection of haptoglobin in the plasma of all
mice was, however, achieved by treating them with LPS, which
induces the synthesis of haptoglobin. Mouse haptoglobin, like
the monomeric form of human haptoglobin, hp1, contains one
free sulfydryl group in its a subunit and migrates as a single
tetrameric (ab)2 band, like human haptoglobin type 1-1 indi-
viduals. The human hp2 protein a subunit, in contrast, con-
tains two free sulfydryl groups and forms a series of hetero-
multimers in the presence of hp1 proteins. Thus, in human
type 2-1 heterozygotes, haptoglobin migrates as a ladder dur-
ing gel electrophoresis. A similar ladder of haptoglobin hetero-
multimers, detectable in the Apo-Hp2 mice after LPS treat-
ment, demonstrates that the haptoglobin hp2 protein is
secreted in combination with the type 1-like mouse haptoglo-
bin. Human haptoglobin was readily detected in the plasma of
(homozygous) Apo-Hp2 mice having two copies of the trans-
gene, even without LPS treatment. Plasma from human type
2-1 heterozygous individuals yields a ladder with up to 9 iden-
tifiable bands. But only three bands are detected in the plasma
of Apo-Hp2 mice, with the first being the heaviest. This pattern
is very similar to that seen in individuals having the haptoglo-
bin 2-1-modified phenotype (23), which is caused by the pro-
duction of less hp2 protein than hp1 (16). Polyacrylamide gel
electrophoresis analysis of plasma from the Apo-Hp2 mice,
therefore, demonstrates that the human haptoglobin is made
and secreted in these mice, but the amount of the human hp2
protein is less than the mouse protein, consistent with the
mRNA data presented above, showing that the expression of
the Hp2 transgene is somewhat lower than that of the endog-
enous mouse gene.
In marked contrast to these observations with the Apo-Hp2
mice, no human haptoglobin was detectable in the plasma of
Hprt-Hp2 mice, even after LPS-treatment, although the endog-
enous mouse haptoglobin was normally present.
DISCUSSION
Our results show that the chromosomal location of a trans-
gene markedly and with a considerable degree of predictability
affects the levels of its expression. Thus the Neo gene in the
Hprt locus is expressed in many tissues of the Hprt-Hp2 mice
at a uniform level, reflecting the ubiquitous pattern of the Hprt
gene expression. However, although the Neo gene is driven by
a strong viral promoter, its expression in the Hprt locus is
relatively low. In contrast, the tissue expression of the same
FIG. 6. Polyacrylamide gel electro-
phoresis of plasma isolated from
mice treated (1) or untreated (2)
with LPS. LPS 1 indicates the mice for
24 h after LPS injection. Free hemoglobin
(Free Hb) and the hemoglobin-haptoglo-
bin complexes (Hp 1-1 or Hp 2-1) are de-
tected by benzidine staining. Human
plasma haptoglobins from individuals
with haptoglobin types 2-1 and 1-1 are
shown for comparison. WT, wild type.
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Neo gene in the apoAI-CIII region of the Apo-Hp2 mice takes on
the same strong expression pattern as the apolipoprotein locus,
which is highly expressed in the liver and intestine. Expression
in the liver of the Neo gene in the apoAI-CIII locus is at least
9-fold that of the same gene in the Hprt locus.
In contrast to the Neo gene with its viral promoter, the liver
expression in the Hprt-Hp2 mice of the hHp2 transgene driven
by its own promoter sequence was only detectable by RT-PCR.
This agrees with earlier work in which a sequence that in-
cluded the 1.1-kilobase pair promoter of hHp2 gene was not
able to support high levels of liver expression of reporter genes
randomly inserted into the genome as transgenes (12, 13),
despite its being sufficient for liver-specific transient expres-
sion of the gene in hepatic cells in tissue culture (11). Thus,
high levels of liver expression of the haptoglobin gene require
not only a liver-competent promoter but also enhancer ele-
ment(s) outside of the 9-kb DNA containing the hHp2 gene. The
apoAI-CIII region, but not the Hprt locus, can supply the en-
hancer element(s), and the hHp2 transgene inserted close to
the Apoa-1 gene is expressed in the liver at approximately 70%
that of the level of the endogenous mouse Hp gene. The apoAI-
CIII region is also known to contain enhancers that functions
in the intestine, and the expression of the hHp2 transgene in
this tissue in the apoAI-CIII locus was five times that of the
endogenous mouse Hp gene in the same tissue. These results
demonstrate that tissue-specific enhancer elements present in
the apoAI-CIII region can interact with the hHp2 promoter as
well as with the viral thymidine kinase promoter and that high
levels of expression of the transgene can be obtained in the liver
by interactions between either of these quite different promot-
ers when they are inserted into the genome within the range of
the tissue-specific enhancers.
Studies using transgenic mice have shown that a 256-bp
sequence from the human apoA-1 gene (24) or a 780-bp se-
quence from the human apoC-III gene (25) are sufficient for
driving their respective gene expression at high levels in the
liver. The cis-elements within these regions that are necessary
for the liver-specific expression have been well characterized
(26). The same studies also showed that neither element is able
to support the expression of the transgenes in the intestine, but
that high levels of intestinal expression of the transgenes can
be achieved by the simultaneous presence of a DNA segment 59
to the apoC-III gene (2500 to 2900) that functions as a clas-
sical enhancer. This distal DNA segment, which contains mul-
tiple regulatory elements, also enhances expression from the
apoA-I and apoC-III promoters in the liver 5- to 10-fold in the
tissue culture system (24). The enhancement of expression in
both the liver and the intestine of the Neo-hHp2 transgenes
when inserted into the mouse apoAI-CIII region is most likely
the consequence of similar interactions.
Unusual aberrant expression of a foreign gene in a particular
transgenic mouse line is frequently attributed to chromosomal
position effect, although proving this effect is often difficult. In
one such case of an aberrant tissue expression of a transgene,
Al-Shawi et al. (27) demonstrated that the expression patterns
of the transgene changed by recovering and reintroducing it
into the secondary transgenic mice. Position independence of
transgene expression can be obtained when relatively large
genomic segments are introduced or when the transgene is
attached to a sequence for matrix attachment sites (or scaffold
attachment sites) (28) or to very strong enhancers such as the
locus-controlling region of the b-globin genes (29). Our work
clearly demonstrates how expression levels in various tissues is
affected by interaction between the promoter elements of the
introduced transgene and enhancers that reside near the loca-
tion of the transgene. It will be of interest to test how the
introduction of matrix attachment sites or a locus-controlling
region will influence the expression patterns of endogenous
genes near a chosen chromosomal insertion site.
The predictable expression of the Neo and hHp2 transgene in
the liver of the Apo-Hp2 mice demonstrates the usefulness of
the apoAI-CIII region for introducing a targeted transgene
when expression in the liver is desirable. The transcriptional
properties of the foreign promoters appear to be maintained,
but their promoter activities in the liver and intestine (and
potentially in the adipose tissue) are greatly enhanced. Thus
the acute phase response of the Hp promoter was retained, as
shown by the increase in the hHp2 gene expression, under LPS
stimulation to approximately the same extent as the increase
in endogenous gene expression. Inactivation of the Apoc-3 gene
by an insertion in opposite transcriptional orientation of the
Neo gene at approximately 30 bp 39 to the poly(A) addition
signal sequence was a slight complication in the present exper-
iments, and adjustment of the position of the insertion may be
desirable to eliminate or reduce the influence of the transgene
on expression of the Apoc-3 gene. However, the reduction of
apoCIII expression itself is unlikely to influence the phenotype
ascribable to the transgene, because mice completely lacking
apoCIII are healthy and exhibit only a mild hypotriglyceri-
demia (30).
In conclusion, the ability to control the levels of tissue-spe-
cific expression of a transgene in vivo by choosing both the
promoter driving the gene and the site of chromosomal inte-
gration with its nearby enhancers makes targeted transgenesis
a very versatile approach for achieving a predictable in vivo
function of the transgene. Furthermore, by using repeated in-
sertion of variant transgenes into the same locus, targeted
transgenesis allows the systematic dissection of in vivo pro-
moter functions or effects of subtle structural changes in the
products of the transgenes.
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